Deucravacitinib in PG

Key facts

Sponsor

Dartmouth-Hitchcock Medical Center

Principal Investigator

Brian J. Simmons, MD

Dartmouth-Hitchcock Medical Center

Intervention

Deucravacitinib(drug)

Eligibility

18-70 years · All sexes

Timeline

2024 – 2024

Study locations (1)

• Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →